
Release date: 2024-12-16 11:13:19 Article From: Lucius Laos Recommended: 247
Thrombocythemia is a common blood disease that poses a serious threat to the health of patients. Choosing the right treatment drug and following the correct dosage is the key to controlling the disease. So, as a common drug for treating this disease, what is the recommended dose of anagrelide?
Anagrelide is a drug used to treat thrombocythemia. It maintains normal platelet counts by inhibiting the production of platelets in the bone marrow, thereby reducing the risk of thrombosis and improving the survival of patients. The following are instructions for the use and dosage of anagrelide:
The starting dose for oral administration is usually 0.5 mg once, 4 times a day, or 1 mg once, 2 times a day.
The dose can be adjusted after one week, but the daily dose can be increased by no more than 0.5 mg in a week.
The maximum dose does not exceed 10 mg per day, and the single dose does not exceed 2.5 mg once.
In case of liver dysfunction, the dose should be appropriately reduced.
The starting dose for oral administration is 0.5 mg, taken at once.
The dose can be adjusted after one week, but the daily dose can be increased by no more than 0.5 mg in a week.
The maximum dose is also no more than 10 mg a day, and the single dose is no more than 2.5 mg at a time.
The dosage of anagrelide should be strictly followed by the doctor's instructions. Do not change the dose or stop using it on your own. If you need to adjust the dose, please do it under the guidance of a doctor.
During the use of anagrelide (Agrylin, Anagrelide), a series of indicators need to be monitored regularly to ensure the safety and effectiveness of the drug. These indicators include but are not limited to:
Anagrelide is mainly used to treat thrombocytosis, so regular monitoring of platelet count is crucial. In the early stage of treatment, more frequent monitoring is required, such as once every two days, and then at least once a week until a stable maintenance dose is reached.
In addition to platelet count, changes in other blood cell indicators such as white blood cell count and hemoglobin should also be paid attention to.
Anagrelide may affect liver and kidney function, so liver and kidney function assessment is required, especially for patients with moderate or severe liver damage, special attention should be paid.
Electrolyte balance is essential for maintaining normal physiological function and should also be monitored during the use of anagrelide.
Since anagrelide may affect the cardiovascular system, electrocardiograms should be performed before and during treatment to monitor cardiovascular effects.
Following the doctor's instructions and regularly testing these indicators will help to adjust the drug dosage in a timely manner, ensure the treatment effect and reduce the risk of adverse reactions.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:3492025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:5512024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:3362025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:3502025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:3262025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3922025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:3252025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:3002025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643